Sugi Predict

Sugi Predict / Compounds / SCHEMBL407414

SCHEMBL407414

SCHEMBL407414

O=S(=O)(NCc1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 1.00
▸ CA12 O43570 4/20 0.76
▸ CA9 Q16790 2/20 0.76
▸ LMNA P02545 2/20 0.76
▸ SMN1; SMN2 Q16637 1/20 0.76
▸ CYP1A2 P05177 1/20 0.76
▸ CYP3A4 P08684 1/20 0.76
▸ ATM Q13315 1/20 0.76
▸ L3MBTL1 Q9Y468 1/20 0.76
▸ CA2 P00918 3/20 0.73
▸ CA1 P00915 2/20 0.73
▸ ALDH1A1 P00352 4/20 0.69
▸ CA7 P43166 2/20 0.65
▸ CA14 Q9ULX7 2/20 0.65
▸ POLB P06746 2/20 0.64
▸ KDM4E B2RXH2 1/20 0.63
▸ SLC12A2 P55011 1/20 0.62
▸ SLC12A5 Q9H2X9 1/20 0.62
▸ PRMT1 Q99873 1/20 0.61
▸ HDAC2 Q92769 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3516799 0.98 KEAP1 (0.96) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL21048461 0.90 KEAP1 (0.81) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL12550095 0.88 KEAP1 (0.79) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL2831966 0.87 CYP19A1 (0.78) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL198318 0.87 CA12 (1.00) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL4663044 0.87 KEAP1 (0.76) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL4662845 0.87 KEAP1 (0.76) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL5143984 0.87 KEAP1 (0.76) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL4662893 0.87 SMN1; SMN2 (1.00) KEAP1CA12CA9LMNASMN1; SMN2
SCHEMBL6283786 0.87 KEAP1 (0.76) KEAP1CA12CA9LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108409612-A A kind of method that N- benzyl benzenesulfonamides are catalyzed and synthesized by boric acid/Catalyzed by Oxalic Acid system under microwave radiation 福建医科大学 2018-08-17 — — CN claimed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US claimed
US-4144140-A Method for the preparation of additives in organo-aluminum electrolyte media SIEMENS AKTIENGESELLSCHAFT (DE) 1979-03-13 — — US claimed
US-4071526-A Method for the preparation of additives in organo-aluminum electrolyte media SIEMENS AKTIENGESELLSCHAFT (DT) 1978-01-31 — — US claimed
JP-56026865-A — — None — — JP disclosed
EP-4716529-A2 COMPOUNDS THAT RE-ACTIVATE MUTANT P53 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) 2026-04-01 — — EP disclosed
WO-2024243343-A2 COMPOUNDS THAT RE-ACTIVATE MUTANT P53 KARANICOLAS JOHN (US) 2024-11-28 — — WO disclosed
CN-118724765-A Method for preparing sulfonamide derivative by using low-cost metal catalysis 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) 2024-10-01 — — CN disclosed
CN-116947712-A Synthesis method of sulfonamide organic compound 苏州华道生物药业股份有限公司 2023-10-27 — — CN disclosed
US-20230339959-A1 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) 2023-10-26 — — US disclosed
US-20230339959-A1 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) 2023-10-26 — — US disclosed
US-11746112-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) 2023-09-05 — — US disclosed
US-4629810-A HERBICIDES CIBA-GEIGY CORPORATION (US) 1986-12-16 — — US disclosed
US-4510325-A Phenyl sulfonamides CIBA-GEIGY CORPORATION (US) 1985-04-09 — — US disclosed
US-4479821-A HERBICIDES, PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1984-10-30 — — US disclosed
US-4468245-A N-(2,3-Epoxypropylene)-n-aralkylsulfonamide and herbicidal compositions containing the same MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) 1984-08-28 — — US disclosed
US-4443245-A HERBICIDES, PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1984-04-17 — — US disclosed
US-4425154-A HERBICIDES, PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1984-01-10 — — US disclosed
US-4419121-A HERBICIDES CIBA-GEIGY CORPORATION (US) 1983-12-06 — — US disclosed
JP-S5626865-A PREPARATION OF N-SUBSTITUTED-N-BENZYLBENZENE SULFONAMIDE MITSUBISHI CHEM IND LTD 1981-03-16 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746112-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms MYH2, MYLK2, MYO1B KEAP1 2823/4885CA12 2878/4885CA9 2930/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS KEAP1 390/4885CA12 2372/4885CA9 750/4885
US-20230339959-A1 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS MYH2, MYLK2, MYO1B KEAP1 2823/4885CA12 2878/4885CA9 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.